CNOOC starts oil production at South China Sea field
China National Offshore Oil Corporation (CNOOC) has commenced production at the Weizhou 5-3 oilfield development project in the Beibu Gulf Basin of the South China Sea.
With an average water depth of around 35m, the project is expected to reach peak production of approximately 10,000 barrels of oil equivalent per day (boepd) by 2026.
The Weizhou 5-3 Oilfield utilises one self-installing wellhead platform and uses nearby existing facilities for its development.
The production plan includes the commissioning of ten development wells, consisting of seven production wells, two water injection wells and one gas injection well.
CNOOC owns a 51% interest in the Weizhou 5-3 oilfield, while Smart Oil Investment holds the remaining 49% stake.
CNOOC is reputed to be the largest producer of offshore crude oil and natural gas in China and one of the largest independent oil and gas exploration and production companies globally.
The company focuses mainly on the exploration, development, production and sale of crude oil and natural gas.
In China, CNOOC carries out oil and gas exploration and development primarily via independent operations and cooperation projects.
The company has been increasing its reserves and production mainly through independent exploration and exploitation.
As of the end of 2024, around 88.7% of net proved reserves and 85.1% of net production in China were from the company's self-operated oil and gas fields.
In April, CNOOC commenced production at the Wenchang 9-7 Oilfield Development Project in the western Pearl River Mouth Basin.
Furthermore, in March, production began at two additional projects: the Caofeidian 6-4 Oilfield Comprehensive Adjustment project and the Wenchang 19-1 oilfield phase two project.
"CNOOC starts oil production at South China Sea field" was originally created and published by Offshore Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. AI-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world Share The results validate the power of IPA's LENSai™ platform and its proprietary HYFT™ technology, which enables first-principles-based in silico peptide discovery and optimization. Five rationally engineered peptide sequences—AI-optimized for improved stability and peptidase resistance—were tested against benchmark GLP-1 analogs in receptor activation assays. Two lead candidates outperformed or matched Semaglutide under controlled assay conditions. Crucially, the sequences were not discovered by chance. They were designed using HYFT-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets. With GLP-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that AI can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same HYFT-driven approach. 'This is not a one-off success,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We've demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. HYFT-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. It represents a foundational shift in how therapeutics are discovered. The same LENSai-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with GLP-1.' IPA is now considering two complementary preclinical paths for its lead GLP-1 candidates: Injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models. Non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance durability, patient compliance, and ease of administration. The sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches. The significance of this breakthrough extends far beyond GLP-1. The same AI framework and HYFT-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance. This announcement follows IPA's recent success with AI-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT™ technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the LENSai™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery methods; the continued development and potential preclinical or clinical progression of IPA's AI-designed GLP-1 peptide program; the feasibility of next-generation delivery strategies; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of AI-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
Business Upturn
2 hours ago
- Business Upturn
Breakthrough From NOVA Named 'Mushroom Powder Product of the Year' In 2025 Mindful Awards Program
LOS ANGELES, June 12, 2025 (GLOBE NEWSWIRE) — The 2025 Mindful Awards Program, an independent recognition platform highlighting conscious companies and products that mindfully make waves in the ever-expanding world of consumer-packaged goods, today announced that Breakthrough from NOVA , a trailblazer in the realm of women's holistic wellness, has been selected as 'Mushroom Powder Product of the Year' in the 7th annual awards program. Breakthrough from NOVA is a dynamic wellness drink mix for performance, energy, and focus. The functional mushroom powder-based formula is engineered to adapt to the unique demands of women and support the full spectrum of a woman's body, brain, and being. The NSF Certified for Sport® drink mix blends seven adaptogens, including a proprietary, clinically tested, full-spectrum mushroom compound made from six organic U.S.-grown species: cordyceps, lion's mane, reishi, turkey tail, shiitake, and king trumpet. Breakthrough is also beneficial for women navigating GLP-1 regimens as it helps to support gut diversity and microbiome health. Adaptogens like Rhodiola rosea (Rhodiolife®) and cordyceps also help to restore energy and endurance as well as preserve muscle. The formula's D-ribose promotes cellular recovery, and its CBD + biotech targets the ECS, reinforcing hormonal balance and emotional resilience. With lion's mane delivering superior gut-brain support, the gut is better prepared to intake nutrients. Breakthrough's mushrooms are full-spectrum and unextracted, preserving their naturally occurring beta-glucans and polyphenols to offer deeper gut and immune support. In addition, Rhodiolife® has also been clinically tested to help regulate cortisol, support mood and muscles during exercise and enhance recovery. NOVA's patented biotech (DehydraTECH™) delivers CBD with 10x absorption, while D-ribose, a naturally occurring sugar critical to ATP production, helps to fight fatigue and fuel cellular energy. The demand for consumer packaged goods (CPGs) remains largely consistent and constant even as consumer preferences evolve and change. The CPG market size is forecast to increase by USD 1,476.3 billion between 2024 and 2029. In 2025, sustainability is the CPG sector's newest consideration along with health-conscious consumer-driven trends and a shift toward e-commerce. With consumers relying more heavily on third-party validation when making new purchasing decisions, the Mindful Awards help brands and services stand out by showcasing products and services that represent the best in transparent, fair, natural, organic, sustainable, healthy, and delicious innovations. All nominations have been evaluated by an independent panel of experts within the consumer-packaged goods industry. 'Breakthrough isn't just a supplement—it's a science-backed power move for the modern, multidimensional woman, representing a revolutionary fusion of ancient wisdom and biotech-driven performance. Humans are unique and many single-ingredient solutions serve as one size fits all products that don't take into consideration that true wellness is the ability to adapt and empower individual bodies to thrive in every dimension,' said Travis Grant, Managing Director, Mindful Awards. 'Breakthrough's formula makes it a truly adaptive system that tunes itself to what each woman needs most. Mental clarity. Physical power. Recovery. Calm. Balance. Breakthrough meets women exactly where they are and supports them wherever they're going.' With scientifically proven benefits in performance, endurance, energy metabolism, stress resilience, and immune support, Breakthrough is designed to elevate physical, cognitive, and emotional wellness. Clinical trials show increased peak power, stamina, and endurance. 'At NOVA, we believe wellness shouldn't shrink a woman, it should fuel her expansion. Not every woman is the same, so our products, like Breakthrough, celebrate women as the complex, ever-evolving forces of nature they are. Breakthrough was formulated to be a revolution in a packet, challenging what wellness looks like and who it's actually for,' said Kathryn Robinson, Founder of NOVA. 'We're proud to accept the Mindful Award for 'Mushroom Powder Product of the Year!' We remain committed to quality and safety, and we'll continue to deliver multi-dimensional products that give our customers—whether athletes, professionals, moms, or all three—the confidence and results they need in a product they can trust.' The 2025 Mindful Awards winners range from groundbreaking food and beverage products to sustainable household solutions, redefining consumer experiences worldwide. This year's program attracted thousands of nominations from companies all over the world whose innovations enhance daily living, promote sustainability, and improve quality of life. About Mindful Awards The Mindful Awards organization is devoted to honoring mindful companies in the consumer-packaged goods industry that are setting the foundation for our future. Mindful Awards are devoted to providing a forum for public recognition around the achievements in categories Food, Beverage, Snacks, Supplements, Home, and Personal Care. Our mission is to bring awareness to the benefits of mindfulness and its impact on society as a whole. We believe that through mindfulness, we can create a more compassionate and sustainable world. For more information visit About NOVA NOVA emerges as a pioneering force in the realm of women's holistic wellness. As an innovative company, NOVA crafts more than just scientifically-backed products; it creates experiences that deeply resonate with the essence of womanhood for all women. NOVA is a genuine and authentic celebration of women in their entirety. Championing every element of a woman's journey, NOVA equips women with innovative wellness products and a community to design and realize their unique purpose. At the core of NOVA's ethos lies a commitment to excellence, innovation and challenging the status quo, placing the company at the forefront of the wellness revolution. NOVA's products are meticulously designed to cater to the multifaceted needs of diverse women, each blending empowerment, science, and integrity. Steadfast in breaking barriers, NOVA strives to redefine and create new standards that authentically represent women's experiences, endurance, achievements, and transformations because women are as diverse and multi-dimensional as the universe. Media Contact:Travis Grant Mindful Awards [email protected] 949.667.4475
Fast Company
2 hours ago
- Fast Company
Chime IPO: Stock price today as financial services startup makes closely watched Nasdaq debut
Chime Financial is expected to debut on the Nasdaq today. The fintech company's initial public offering (IPO) is one of the most anticipated of 2025, and investors and market watchers will be eagerly waiting to see how the newly public stock performs on its first day of trading. If it performs well, it could signal positive investor appetite for technology public offerings and the IPO market as a whole. Here's what to know about Chime's IPO. What is Chime? Chime Financial, Inc. is a fintech company. It was founded in 2012 and is based in San Francisco. The company offers banking products without the associated fees that traditional banks tack onto accounts. For example, many of Chime's online banking services don't have a minimum balance, or monthly service or overdraft fees. These fees are major drivers of revenue at traditional banks. So how does Chime generate revenue without them? The company says its business model is primarily based on interchange fees, which are the fees that merchants pay when they accept a card payment. Chime's services can be accessed on the web and also via iPhone and Android apps. Chime is not a bank but rather offers banking services. It has partnerships with Bancorp Bank and Stride Bank. A diminished market cap With Chime's IPO, the company is now valued at approximately $11.6 billion, according to CNBC. However, that is less than half of its peak private valuation of $25 billion in 2021. In that year, Chime received a funding round of $750 million. One reason for Chime's high private valuation in 2021, relative to its valuation today, was the pandemic. As Fast Company previously noted, in the early 2020s, fintech companies experienced a surge in service usage from consumers and garnered significant attention from investors as the pandemic unfolded. Much of that excitement for companies operating in the fintech space has subsided in subsequent years. The market turmoil of 2025 has also made investors more cautious about companies operating in the finance sector and initial public offerings in general. In May, another fintech company, the online brokerage firm eToro Group (Nasdaq: ETOR), went public for $52 per share. As of yesterday's close, ETOR shares are trading at $62.96 per share. Chime by the numbers On May 13, Chime filed a Form F-1 with the U.S. Securities and Exchange Commission (SEC). In the F-1 filing, Chime reported the following metrics as of March 31, 2025: Active Chime members: 8.6 million Active member growth rate since Q1 2022: 82% Purchase volume: $121 billion Average revenue per active member (ARPAM): $251 Gross margin: 88% Transaction margin: 67% When is Chime's IPO? Chime priced its shares on Wednesday and is expected to begin trading today: Thursday, June 12, 2025. What is Chime's stock ticker? Chime's stock ticker is 'CHYM.' What exchange will Chime shares trade on? Chime shares trade on the Nasdaq Global Select Market. What is the IPO share price of CHYM? Chime's IPO price is $27 per share. That's higher than the expected IPO price of between $24 and $26. The higher IPO price of $27 per share suggests that Chime believes there is a greater appetite for its shares than previously thought. How many CHYM shares are available in its IPO? According to a company press release, a total of 32 million CHYM were made available in its IPO. Of those shares, Chime offered 25,900,765 Class A shares directly to the public. Existing company shareholders put up the remaining 6,099,235 shares. How much did Chime raise in its IPO? Chime raised approximately $700 million in its initial public offering. That consists of the proceeds from the 25.9 million shares the company sold directly. Chime did not benefit from the sale of the 6 million shares sold by its existing shareholders. How much is Chime worth? At its $27 IPO price, Chime's market cap is now valued at approximately $11.6 billion. What else is there to know? Chime is the latest in a number of closely watched tech-focused IPOs this year. In addition to the aforementioned eToro, stablecoin company Circle Internet Group went public earlier this month. Both stocks have performed well since their debut, raising hopes for the IPO market more broadly.
